ArticleDiabetes, metabolic syndrome and obesity : targets and therapy2020
Comparison of Novel Metabolic Indices in Estimation of Chronic Kidney Diseases in a Southern Chinese Population.
Article in Diabetes, metabolic syndrome and obesity : targets and therapy, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 2 syntheses or guidelines pooled it, 19 citations in OpenAlex.
- Association between diabetic kidney disease and visceral adiposity index: a meta-analysis.BMC nephrology · 2026Pooled it
- Diagnostic value of visceral adiposity index in chronic kidney disease: a meta-analysis.Acta diabetologica · 2023Pooled it
- Clinical study on the value of TyG index combined with systemic immune-inflammation index for screening hospitalized patients with type 2 diabetic kidney disease.Frontiers in endocrinology · 2026Article
- Association between triglyceride-glucose index and chronic kidney disease: results from NHANES 1999-2020.International urology and nephrology · 2024Article
- Association of different obesity indexes with diabetic kidney disease in patients with type 2 diabetes mellitus: a cross-sectional study.Scientific reports · 2024Article
- Association between lipid accumulation product index and chronic kidney disease: A systematic review and meta-analysis.Experimental and therapeutic medicine · 2024Article
- Comparison of TyG and Newly TyG Related Indicators for Chronic Kidney Diseases Estimation in a Chinese Population.Diabetes, metabolic syndrome and obesity : targets and therapy · 2024Article
- The Association of HDL2b with Metabolic Syndrome Among Normal HDL-C Populations in Southern China.Diabetes, metabolic syndrome and obesity : targets and therapy · 2024Article
- Comparison of insulin resistance indices in predicting albuminuria among patients with type 2 diabetes.European journal of medical research · 2023Article
- Interrelation between the lipid accumulation product index and diabetic kidney disease in patients with type 2 diabetes mellitus.Frontiers in endocrinology · 2023Article
- Associations of lipid accumulation product, visceral adiposity index, and triglyceride-glucose index with subclinical organ damage in healthy Chinese adults.Frontiers in endocrinology · 2023Article
- Triglyceride-Glucose Index May Predict Renal Survival in Patients with IgA Nephropathy.Journal of clinical medicine · 2022Article
- The non-linear relationship between triglyceride-glucose index and risk of chronic kidney disease in hypertensive patients with abnormal glucose metabolism: A cohort study.Frontiers in medicine · 2022Article
- Lipid Accumulation Product is Associated with Urinary Albumin-creatinine Ratio in Chinese Prediabitic Population: A Report from the REACTION Study.Diabetes, metabolic syndrome and obesity : targets and therapy · 2021Article
- Prospective Association of Novel Metabolic Indices with Metabolic Syndrome in Middle-Aged and Elderly Chinese.Diabetes, metabolic syndrome and obesity : targets and therapy · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTo determine the optimal cut-off values and evaluate the associations of product of triacylglycerol and glucose (TyG), lipid accumulation product (LAPI), visceral adiposity index (VAI) with chronic kidney diseases (CKD) stratified by sex.
methodsFrom January to April 2018, our team had conducted a large-scale cross-sectional survey that contained 2720 individuals on the southern coast of China. Logistic regression analysis and receiver operating characteristic (ROC) analyses were used to evaluate the optimal cut-off and value of TyG, LAPI, VAI for predicting CKD.
resultsA multivariate logistic regression analysis found that the TyG had the better value of prediction for the presence of CKD for the highest quartile vs the lowest quartile in both males (OR: 3.65; 95% CI, 2.04-6.52; p<0.001) and females (OR: 3.50; 95% CI, 2.20-5.56; p<0.001), followed by LAPI and VAI, when further adjusted for cofounder factors, LAPI and VAI both lost their independence, and only TyG remains its significant association with CKD in both males (OR: 2.81; 95% CI, 1.25-6.30; p<0.001) and females (OR: 3.22; 95% CI, 1.56-6.61; p<0.001). ROC curve showed that TyG had the highest AUC for predicting CKD in males (AUC: 0.618). TyG (AUC: 0.670) and LAPI (AUC: 0.670) both had the highest AUC in females. United predicted models which contain TyG were conducted for predicting CKD in males (AUC: 758) and females (AUC: 0.773) and results indicated that multivariate analysis of TyG and other traditional factors can impressively improve the accuracy of predictive probability for CKD.
conclusionTyG is a priority to the other two novel indices and may become valuable makers and have strong predictive power for predicting CKD, especially in females.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.